Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
136-150 of 2360 results
Mitsubishi Tanabe Pharma inks licensing deal with A. Menarini Asia-Pacific for Spedra (Avanafil)
Mitsubishi Tanabe Pharma, and Singapore-based A. Menarini Asia-Pacific Holdings have entered into a licensing agreement to commercialize and promote SPEDRA (avanafil).
Contract Research & Services > Contract Services > News
Baxalta, Precision BioSciences partner to develop CAR T therapies
By PBR Staff Writer
Baxalta and Precision BioSciences have established global genome editing collaboration in immuno oncology.
Contract Research & Services > Contract Services > News
McKesson agrees to acquire two cancer care companies for $1.2bn
By PBR Staff Writer
McKesson has agreed to acquire two privately held cancer care companies, Vantage Oncology and Biologics, in two transactions totaling $1.2bn.
Contract Research & Services > Contract Services > News
Gilead Sciences launches new grants program to support HIV cure
Gilead Sciences announced that it will provide grants for up to three years to academic institutions, nonprofit organizations and community groups engaged in HIV cure activities.
Contract Research & Services > Contract Services > News
Eisai, PIQUR sign deal to investigate Halaven and PQR309 in patients with TNBC
Eisai and PIQUR Therapeutics have signed an agreement to conduct a Phase 1/2b clinical study to investigate PQR309 in combination with Halaven® (eribulin) in patients with triple-negative breast cancer (TNBC).
Contract Research & Services > Contract Services > News
Philogen expands research and development agreement with AbbVie
Philogen has entered into a second collaboration with AbbVie to discover and develop novel types of armed antibody products.
Contract Research & Services > Contract Services > News
NanoViricides inks deal with University of Pittsburgh for ocular resting of drug candidates
NanoViricides has entered into an agreement with the University of Pittsburgh for the testing of its nanoviricides drug candidates in standard animal models of ocular virus infections.
Contract Research & Services > Contract Services > News
Seattle Genetics unveils commercial and regulatory progress under ADCETRIS collaboration with Takeda
Seattle Genetics will receive a one-time $20m milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda).
Contract Research & Services > Contract Services > News
Takeda secures rights to Mersana’s XMT-1522 outside US and Canada
Mersana Therapeutics and Takeda Pharmaceutical Company have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the US and Canada.
Contract Research & Services > Contract Services > News
Eisai, Esteve sign deal to co-promote anti-epilepsy drug Fycompa in Spain
Eisai has entered into a new agreement with Esteve to co-promote Fycompa (perampanel) in Spain from February 2016.
Contract Research & Services > Contract Services > News
Ligand inks OmniAb platform license deal with Tizona Therapeutics
Ligand Pharmaceuticals has entered into a worldwide license agreement with Tizona Therapeutics, an immunology company developing next generation therapies for cancer and autoimmune disease.
Contract Research & Services > Contract Services > News
Teva and AbCellera sign deal to discover rare monoclonal antibodies
Teva Pharmaceutical Industries and AbCellera have entered into a collaborative research agreement whereby AbCellera will apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies.
Contract Research & Services > Contract Services > News
Eisai acquires license from HUYA to develop HDAC inhibitor HBI-8000
Eisai has entered into an exclusive license agreement with HUYA Bioscience International to develop and market the oral histone deacetylase (HDAC) inhibitor HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.
Contract Research & Services > Contract Services > News
Bristol-Myers Squibb, Pfizer collaborate with Portola to develop andexanet alfa in Japan
Bristol-Myers Squibb and Pfizer have entered into a collaboration agreement with Portola Pharmaceuticals to develop and commercialize the investigational agent andexanet alfa in Japan.
Contract Research & Services > Contract Services > News
Avera Medical, Epic Sciences partner on cancer precision medicine clinical trials
Epic Sciences and Avera Medical Group have formed a collaboration on feasibility studies to better understand the effectiveness of personalized cancer treatments as part of novel ovarian and breast cancer clinical trials.
Contract Research & Services > Contract Services > News
136-150 of 2360 results